Efficacy and safety of cardiac myosin inhibitors for symptomatic hypertrophic cardiomyopathy: a meta-analysis of randomized controlled trials [PDF]
Frontiers in Cardiovascular MedicineIntroductionHypertrophic cardiomyopathy (HCM) is a common genetic heart disorder. It is characterized by left ventricular hypertrophy and impaired cardiac function, with forms categorized into obstructive (oHCM) and nonobstructive (nHCM).
Madiha Shāh
exaly +4 more sources
Cardiac Myosin Inhibitors in Hypertrophic Cardiomyopathy: From Sarcomere to Clinic [PDF]
International Journal of Molecular SciencesHypertrophic cardiomyopathy (HCM) is a primary myocardial disease characterized by unexplained left ventricular hypertrophy, often resulting from pathogenic variants of sarcomeric protein genes. Conventional treatments, such as the use of beta blockers or calcium channel blockers, focus on symptomatic control but do not address the underlying ...
, Takahiro Okumura, Seiya Kato
exaly +4 more sources
Cardiac Myosin Inhibitors as a Novel Treatment Option for Obstructive Hypertrophic Cardiomyopathy: Addressing the Core of the Matter [PDF]
Journal of the American Heart Association, 2022 Ahmad Masri, Iacopo Olivotto
exaly +4 more sources
Myosin inhibitors for treatment of hypertrophic cardiomyopathy. [PDF]
Cochrane Database Syst RevThis is a protocol for a Cochrane Review (intervention). The objectives are as follows: Primary objective To assess the effects of myosin inhibitors compared to usual care or placebo on exercise capacity, need for septal reduction therapy, and all-cause mortality in people with hypertrophic cardiomyopathy (HCM).
Quill S +6 more
europepmc +4 more sources
Cardiac myosin inhibitors: a silver lining for an old disease [PDF]
Open HeartSandeep Singh +2 more
doaj +4 more sources
Targeting the Sarcomere: Myosin Inhibitors as the Revolutionary Game Changer in Hypertrophic Cardiomyopathy [PDF]
Reviews in Cardiovascular MedicineHypertrophic cardiomyopathy (HCM) represents the most common inherited cardiac disease and a leading cause of heart failure, arrhythmias, and sudden cardiac death in young individuals.
Farbod Sedaghat-Hamedani +2 more
doaj +2 more sources
Cardiac myosin inhibitors in hypertrophic cardiomyopathy. [PDF]
J Cardiovasc ImagingAbstract Mavacamten, the first selective and reversible cardiac myosin inhibitor (CMI), has been introduced to the clinical arena for the treatment of obstructive hypertrophic cardiomyopathy (HCM). By reducing excessive actin-myosin cross-bridging, this agent decreases myocardial contractility and alleviates the dynamic left ventricular ...
Lim J, Kim HK.
europepmc +3 more sources
Efficacy of cardiac myosin inhibitors mavacamten and aficamten in hypertrophic cardiomyopathy: a systematic review and meta-analysis of randomised controlled trials [PDF]
Open HeartBackground Unlike other suggested therapies, myosin inhibitors have been shown to change the course of hypertrophic cardiomyopathy by altering the contractile mechanics of cardiomyocytes.
Ayesha Aman +7 more
doaj +2 more sources
Specificity of blebbistatin, an inhibitor of myosin II [PDF]
Journal of Muscle Research and Cell Motility, 2004 Blebbistatin is a small molecule inhibitor discovered in a screen for inhibitors of nonmuscle myosin IIA. We have examined the specificity and potency of the drug by assaying its effects on the actin-activated MgATPase assay of diverse members of the myosin superfamily.
Aaron F Straight +2 more
exaly +3 more sources
Efficacy and safety of myosin inhibitors for symptomatic hypertrophic cardiomyopathy: systematic review and meta-analysis [PDF]
Archives of Medical Science: Atherosclerotic DiseasesIntroduction Hypertrophic cardiomyopathy (HCM) is a common genetic cardiac disorder associated with significant morbidity and mortality. Cardiac myosin inhibitors (MIs), including mavacamten and aficamten, offer a novel therapeutic approach for HCM ...
Mohammad Hazique +8 more
doaj +2 more sources